Hua-Chen Chang

Permanent URI for this collection

https://hdl.handle.net/1805/6687

Browse

Now showing 1 - 10 of 13

EFFECTS OF TYPE VI COLLAGEN ON MACROPHAGES
(Office of the Vice Chancellor for Research, 2011-04-08) Voiles, Larry; Han, Ling; Lupov, Ivan P.; Anderson, Bailey; Melnikov, Lonya; Pottratz, Sarah Marie; Chang, Hua-Chen
Emphysema is an abnormal inflammatory response of the alveoli that lose their elasticity due to destruction of alveolar septi. Collagen, an extracellular matrix protein (ECM), is expressed in the lung, which is important in maintaining the integrity of the tissue. Destruction of the ECM components in the alveolar structure contributes to the development of emphysema. We have found that the gene expression of type VI collagen (COL6A1) is higher in the lungs of emphysema patients as compared to that from normal controls. Type VI collagen (COL6) is found in the pulmonary interstitial compartment where massive macrophages are infiltrated in the inflammatory environment. The hypothesis is that excessive COL6 activates macrophages to mediate inflammatory responses, which may contribute to the pathogenesis of emphysema. The goal is to define the effects of type VI collagen on macrophages. Results from murine bone marrow derived macrophages showed a marked increase in the numbers of CD86-positive cells after soluble COL6 stimulation. To further support the stimulatory function of COL6, human THP-1 cells as well as primary monocytes produced inflammatory cytokines IL-12 and IFNγ following COL6 stimulation. Taken together, our data has demonstrated the stimulatory effects on macrophages by COL6 stimulation, which may mediate the inflammatory responses in the pathogenesis of emphysema.
ENHANCING THE TUMOR FIGHTING CAPACITY OF NK CELLS THROUGH THE USE OF SOYPEPTIDE
(Office of the Vice Chancellor for Research, 2012-04-13) Lewis, David; Chang, Hua-Chen; Han, Ling; Voiles, Larry; Henriquez, Sarah M.P.
Natural killer or (NK) cells are important components of the innate immune system, which play a major role in the rejection of tumors, and virally in-fected cells. By producing pro-inflammatory cytokines such as IFN-gamma, NK cells are able to exert immunoregulatory functions that influence the adaptive immunity of other immune cells. Due to its critical role in tumor inhibition, researchers, utilizing various cytokines, including IL-12 and IL-2, have fervently pursued the manipulation of NK activity. NK cells respond to cytokines in a dose-dependent manner; however, the toxicity of certain cy-tokines (like IL-2) in high doses prohibits their widespread clinical use. Therefore, efforts to activate NK cells without requiring high doses of cyto-kines is warranted. We recently exploited a soy derived dietary peptide called lunasin to improve the immune functions. The hypothesis was that the lunasin peptide has stimulatory effects on immune cells. To test this hy-pothesis, human peripheral blood mononuclear cells (PBMCs) of healthy do-nors were stimulated with and without lunasin in combination with cytokines IL-12 or IL-2. Our results showed that the lunasin peptide exerts a robust synergistic effect when combined with the selected cytokines. This effect ap-pears to regulate the expression of a number of genes that are important for NK activity. Our findings support the potential clinical use of lunasin in com-bination with cytokine to enhance the tumor fighting capacity of NK cells.
TYPE VI COLLAGEN STIMULATES MACROPHAGES TO PROMOTE INFLAMMATION
(Office of the Vice Chancellor for Research, 2012-04-13) Voiles, Larry; Han, Ling; Lupov, Ivan; Chang, Hua-Chen
Collagen VI (COL6), an extracellular matrix protein (ECM), is important in maintaining the integrity of the tissue. Our recent findings have demonstrat-ed that excess COL6 is present in the lungs of comorbid patients with em-physema and adenocarcinoma. COL6 localized in the pulmonary interstitium is likely to interact with endothelial, epithelial and infiltrated pulmonary mac-rophages. The hypothesis is that excessive COL6 activates macrophages to promote inflammation, which may exacerbate pulmonary diseases. To test our hypothesis, bone marrow derived macrophages or macrophage cell lines were stimulated with soluble COL6 followed by analysis of activation markers and pro inflammatory cytokines. And results showed an increase in the number of CD86 positive cells and the levels of IL-12 and IFNγ production following stimulation. Taken together, our data have provided a link between increased amounts of COL6 and subsequent immune responses, which may play a role in the pathogenesis of pulmonary inflammatory diseases.
Effects of Soy Peptide on Dendritic Cells
(Office of the Vice Chancellor for Research, 2013-04-05) Shipman, Kaylee; Tung, Chun-Yu; Han, Ling; Patel, Amy; Corn, Caleb; Chang, Hua-Chen
Innate immunity is mediated by effector cells, including NK cells, dendritic cells (DCs), macrophages, and polymorphonuclear phagocytes, which can respond immediately after activation through receptors encoded by germ-line genes. Innate immune responses represent the first line of defense in immunosurveillance. Interventions that enhance the functions of innate immunity will be an important armamentarium to human health. We recently exploited a natural dietary soy peptide called lunasin to improve the immune functions. The hypothesis was that lunasin peptide has stimulatory effects on immune cells. To test this hypothesis, human peripheral blood mononuclear cells (PBMCs) of healthy donors were stimulated with or without lunasin. We found that lunasin is capable of stimulating DCs to up-regulate chemokines (CCL2, CCL3, and CCL4), cytokines (TNFα and IFNα), and co-stimulatory molecules (CD80, CD86). In addition, lunasin-treated DCs can provide NK with required signals for activation. Taken together, our results support the immunomodulatory activity of soy peptide on DCs, which leads to enhancement of innate immunity.
Enhancement of Cancer Immunotherapy Using Immune Modulating Peptides
(Office of the Vice Chancellor for Research, 2013-04-05) Chang, Hua-Chen; Han, Ling; Lewis, David; Tung, Chun-Yu; Srinivasan, Mythily; Robertson, Michael J.; Yeh, Wu-Kuang
Immune Peptide Therapeutics (IPT) LLC, an Indiana-based small business and its research partner Indiana University previously identified a novel property of lunasin as a distinct class of immune modulating agent that enhances anti-tumor immunity, which may promote disease-free survival by limiting tumor progression, and thus prolong lives of cancer patients. Lunasin, a synthetic 43-amino acid peptide, was originally isolated from soybeans. Our studies have demonstrated that lunasin exerts robust synergistic effects with cytokines on augmenting IFNγ and granzyme B expression by Natural Killer (NK) cells, which is associated with increased tumoricidal activity of NK cells. In addition, this combination regimen is capable of rescuing IFNγ production ex vivo by NK cells from chemotherapy-treated Non-Hodgkin’s Lymphoma (NHL) patients who are immunocompromised with acquired immune deficiency. The long-term goal is to develop an efficacious immunotherapy which will impact the treatment and improve the clinical outcomes for NHL patients. The dose-response study indicates the optimum concentration of lunasin is at the range of μM, which would undermine its use in clinical studies. To enhance the medicinal value lunasin must be optimized for in vitro and in vivo efficacy. The objective is to develop a second generation of lunasin, which will increase its potency to improve the performance. In this study we have implemented several strategies to design and modify the prototype. The newly developed peptide called IPT.103 has 15 amino acids that are in the D-isoform configuration. Activity of IPT.103 has been tested in vitro with EC50 of 0.78 μM as compared to 4.54 μM for lunasin. IPT.103 also has in vivo activity on enhancing the serum levels of IFNγ production using a mouse model. Taken together, we have developed a peptide derivative (IPT.103) that deviates from its parental type lunasin to increase intellectual merit for commercialization as well as support clinical application.
Activation of Natural Killer Cell by Lunasin and Cytokine
(Office of the Vice Chancellor for Research, 2014-04-11) Kyazike, Sharifah; Lewis, David; Tung, Chun-Yu; Han, Ling; Chang, Hua-Chen
Cancer immunotherapy is one of the emerging therapeutic strategies to harness the immune system to eradicate chemotherapy-resistant cancerous cells. NK cells can recognize and eliminate cancer cells before adaptive immunity is developed. Human NK cells can be divided into 2 major subsets based on their surface expression of CD56. NK cells with CD56 bright populations are major cytokine producers, while NK cells expressing CD56 dim have higher lytic activity. Due to the role of NK cells in cancer surveillance, any approach to enhance their activity may augment cancer treatment. We have recently shown that soypeptide Lunasin is a novel immune modulating agent that, together with cytokines, enhances IFN- γ and Granzyme B expression by NK cells. This synergism augments the natural cytotoxicity of NK cells against various tumors in vitro as well as in the xenograft model. The objective of this study is to evaluate the effects of Lunasin on antibody-dependent cellular cytotoxicity (ADCC) activity of NK cells against Rituximab-coated human B-lymphoma Raji cells. We also evaluated the expression of several markers involved in NK-mediated tumorcidal activity using flow cytometry. Together, these results suggest that Lunasin could enhance the efficacy of NK cell-based immunotherapy for cancer.
Modulating NK-mediated Immunity by Lunakine
(Office of the Vice Chancellor for Research, 2014-04-11) Chang, Hua-Chen; Tung, Chun-Yu; Lewis, David; Han, Ling; Srinivasan, Mythily; Robertson, Michael J.; Yeh, Wu-Kuang
Despite the plethora of immune modulating agents available in cancer treatment, their effectiveness relies on a functional immune system. However, the adverse side effects by chemotherapy impede the therapeutic benefits from immunotherapy. It remains a major challenge to prevent relapse for cancer patients who have already undergone rigorous chemotherapy. Lunasin, a 43-amino acid peptide, was originally isolated from soybeans. Our team has recently discovered a novel function of lunasin as an immune modulating agent that exerts robust synergistic effects imposed by several therapeutic cytokines. Such synergism strongly augments IFNγ and granzyme B expression by Natural Killer (NK) cells, which is associated with increased tumoricidal activity. The combination regimen with lunasin and cytokine is capable of restoring NK activation from lymphoma patients with chemotherapy-induced immune dysfunction. Our results support the potential application of lunasin to improve the therapeutic effects of existing cytokine treatment that has been used to eliminate residual tumors cells from lymphoma patients after chemotherapy. We designate lunakine as new formulation by combing lunasin and selected cytokine (filed for US Patent Cooperation Treat). In working with Indiana University and Technology Corporation (IURTC), we have started a startup company, Immune Peptide Therapeutics (IPT), LLC. Our mission is to develop a more efficacious immunotherapy that prevents relapse and confers progression-free survival for cancer patients. With the support from FORCES, our team has successfully developed a second generation of lunasin called IPT.103 that deviates from its parental type. Activity of IPT.103 has been tested in vitro with EC50 of 0.78 μM as compared to 4.54 μM for lunasin, indicating an improved potency to induce IFNγ production by NK cells. The newly developed peptide IPT.103 is expected to strengthen the intellectual property (IP) position for commercialization. We are currently working on tumor models for preclinical assessment of IPT’s regimens in immunotherapy for lymphoma.
Activation of Dendritic Cells by Soypeptide Lunasin: Implication in Vaccine Adjuvant
(Office of the Vice Chancellor for Research, 2014-04-11) Flores, Sarah; Dong, Melissa; Tung, Chun-Yu; Chang, Hua-Chen
Adjuvants enhance the immunogenicity of vaccines and improve the immune responses. Although many adjuvants are currently used in research, FDA approved aluminum salt (Alum) remains the most often used in human vaccines. Alum is known to promote the Th2 immune response and enhance antibody production, but is less efficient on eliciting Th1 and CTL cellular responses. Thus, it is prudent to improve the effectiveness of current adjuvants or to develop a novel alternative adjuvant. We have recently identified lunasin, a seed peptide from soybeans, as a novel immune modulator. The objective is to define the effectiveness of lunasin peptide as an adjuvant that can enhance the protective immunity of vaccines. Our studies have revealed stimulatory effects of lunasin on dendritic cells (DCs) by regulating expression of a number of genes that are important for immune responses. Lunasin-treated human conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86) but also exhibited up-regulation of chemokines (CCL2, CCL3, CCL4) and cytokine (IL-1β). To determine the function of lunasin-treated cDCs, these cells were co-cultured with allogeneic human peripheral blood CD4+ T cells for 7 days in the mixed lymphocyte reaction. Lunasin-treated cDCs induced almost 2-fold higher proliferation of allogeneic CD4+ T cells when comparing with a sham treatment. To verify the in vivo effects, lunasin was administered into mice. Increased CD86 expression was found in cDCs from spleens of mice treated with lunasin. Furthermore, mice vaccinated with lunasin-adjuvanted ovalbumin (OVA) had reduced tumor growth following challenging with OVA-expressing A20 B-lymphoma cells. Taken together, our data suggest that lunasin may act as a vaccine adjuvant by targeting DCs to enhance and modulate the immune responses to antigens.
Overexpression of type VI collagen in neoplastic lung tissues
(Spandidos, 2014-08) Voiles, Larry; Lewis, David E.; Han, Ling; Lupov, Ivan P.; Lin, Tsang-Long; Robertson, Michael J.; Petrache, Irina; Chang, Hua-Chen; Department of Biology, IU School of Science
Type VI collagen (COL6), an extracellular matrix protein, is important in maintaining the integrity of lung tissue. An increase in COL6 mRNA and protein deposition was found in the lungs of patients with pulmonary fibrosis, a chronic inflammatory condition with a strong association with lung cancer. In the present study, we demonstrated overexpression of COL6 in the lungs of non-small cell lung cancers. We hypothesized that excessive COL6 in the lung interstitium may exert stimulatory effects on the adjacent cells. In vitro stimulation of monocytes with COL6 resulted in the production of IL-23, which may promote tumor development in an environment of IL-23-mediated lung inflammation, where tissue modeling occurs concurrently with excessive COL6 production. In addition, COL6 was capable of stimulating signaling pathways that activate focal adhesion kinase and extracellular signal‑regulated kinase 1/2 in lung epithelial cells, which may also facilitate the development of lung neoplasms. Taken together, our data suggest the potential role of COL6 in promoting lung neoplasia in diseased lungs where COL6 is overexpressed.
Lunasin alleviates allergic airway inflammation while increases antigen-specific Tregs
(PLoS, 2015-02-03) Yang, Xiaowei; Zhu, Jingjing; Tung, Chun-Yu; Gardiner, Gail; Wang, Qun; Chang, Hua-Chen; Zhou, Baohua; Department of Pediatrics, IU School of Medicine
Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In this study we demonstrate that lunasin can effectively suppress allergic airway inflammation in two murine models of asthma. In an OVA+Alum sensitization model, intranasal lunasin treatment at the time of OVA challenges significantly reduced total cells counts in bronchoalveolar lavage (BAL) fluid and eosinophilia, peribronchiolar inflammatory infiltration, goblet cell metaplasia and airway IL-4 production. In an OVA+LPS intranasal sensitization model, lunasin treatment either at the time of sensitization or challenge has similar effects in suppress allergic airway inflammation including significantly reduced total cell and eosinophil counts in BAL fluid, inflammatory gene Fizz1 expression in the lung, and IL-4 production by OVA re-stimulated cells from mediastinal lymph nodes. We further show that intranasal instillation of OVA+lunasin significantly increases OVA-specific regulatory T cell (Treg) accumulation in the lung comparing to OVA only treatment. Taken together, our results suggest lunasin as an anti-inflammatory agent can be potentially used in asthma therapy or as an adjuvant to enhance the induction of antigen-specific Tregs and thus boost the efficacy of allergy immunotherapy.

Browse

Browsing Hua-Chen Chang by Issue Date

Results Per Page

Sort Options